Health Care · Pharmaceutical Preparations

ALDX Aldeyra Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 134123596 filings
Russell 2000

ALDX at a glance

Aldeyra Therapeutics, Inc. (ALDX, SEC CIK 1341235) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 21 institutional investment managers tracked by SignalX reported holding Aldeyra Therapeutics, Inc. (ALDX) shares worth $12.4 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by DEPTULA-HICKS DARLENE M on November 12, 2026 of 7,500 shares at $0.65 per share.
  • In the last 90 days, ALDX insiders reported 3 open-market purchases ($140K) and 0 open-market sales ($0) on Form 4, a net purchase of $140K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
3 buys · 0 sells
Net +$140K
13F holders
21 funds
$12.4M · −2 vs prior quarter
Latest 8-K
Nov 17, 2026
Item 3.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Regulatory risk: 2026 Complete Response Letter triggered FDRR submission on October 26, 2026, with uncertain timing and approval outcome
  • Operational risk: Third-party reproxalap manufacturer received Form 483 deficiencies in August 2025, later classified VAI
  • Competitive risk: Dry-eye market includes Restasis, Xiidra, Cequa, Eysuvis, Tyrvaya, Miebo, Vevye, and Tryptyr
  • Financial risk: Nine-month 2026 net loss $12.7 million, accumulated deficit $496.6 million, requiring substantial additional financing
  • Legal risk: FDA “radical transparency” policy creates potential Securities Class Action and SEC scrutiny following public Complete Response Letters

Management Discussion & Analysis

  • Quarterly revenue: $0, with no approved products and no product sales revenue
  • Net loss $3.8M vs $7.7M YoY, loss from operations $4.1M vs $8.0M
  • Reproxalap: primary late-stage R&D focus, approximately 30% of quarterly R&D expenses
  • Cash $41.0M at September 30, 2026, operating cash use $13.8M year-to-date
  • FDA Complete Response Letter and FDRR pending, ADX-2191 retinitis pigmentosa program suspended, AbbVie option unexercised

AI summary of the ALDX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 17, 2026Full analysis →

Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule

  • Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum
  • No immediate delisting, Nasdaq listing remains effective
Filed Nov 9, 2026Full analysis →

Item 8.01: Other Events

  • FDA review-jurisdiction transfer requested from Ophthalmology to Hematologic Malignancies 2 for ADX-2191’s PVRL program
  • SPA protocol withdrawn, eliminating prior FDA agreement on trial design and planned analysis
Filed Sep 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Aldeyra plans a Formal Dispute Resolution Request to FDA’s Office of New Drugs after three complete response letters for reproxalap
  • OND meeting expected in Q4 2026, but FDRR timing and outcome remain uncertain

Item 7.01: Regulation FD Disclosure

  • Aldeyra plans to appeal FDA’s March 16, 2026 rejection of reproxalap’s dry-eye NDA through a Formal Dispute Resolution Request
  • FDRR submission and FDA Office of New Drugs meeting expected in Q4 2026, creating a potential approval-pathway catalyst

Item EX-99.2: Item EX-99.2

  • Aldeyra plans an FDA Formal Dispute Resolution Request in Q4 2026 to appeal reproxalap’s March 16, 2026 rejection for dry eye disease
  • Regulatory risk remains high: three Complete Response Letters, with the latest citing insufficient totality of evidence rather than requesting another trial

Item 8.01: Other Events

  • Aldeyra plans an FDA dispute resolution request challenging the March 16, 2026 rejection of reproxalap for dry eye disease
  • Reproxalap approval remains uncertain, creating a regulatory catalyst and significant binary risk for investors

AI summaries of ALDX 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ALDX

Don't miss the next ALDX filing

  • Alerts as it files. A push when ALDX files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ALDX, by share count.
  • Ask anything. An AI agent that reads every ALDX filing and answers with sources.

ALDX alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
DEPTULA-HICKS DARLENE MBuyNov 12, 2026$0.65
DOUGLAS RICHARDBuyNov 11, 2026$0.64
Alfieri MichaelBuyNov 11, 2026$0.65
Miller-Rich NancyAJun 9, 2026-
Bronstein BenAJun 9, 2026-
DOUGLAS RICHARDAJun 9, 2026-
Bronstein BenAJun 9, 2026-
DOUGLAS RICHARDAJun 9, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$42.8M-$60.1M-$35.3M
Net Income-$37.5M-$55.9M-$33.8M
Balance Sheet
Total Assets$148.3M$104.6M$72.1M
Equity$119.8M$71.0M$44.3M
ROE-31.3%-78.7%-76.5%
Per Share
EPS$-0.64$-0.94$-0.56
Cash Flow
Operating CF-$30.3M-$43.2M-$33.3M
CapEx$0--

Source: XBRL data in Aldeyra Therapeutics, Inc. (ALDX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ALDX share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ALDX shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202621$12.4M
Q2 202623$31.1M
Q1 202623$29.6M
Q4 202523$81.1M
Q3 202524$83.1M
Q2 202525$51.9M
Q1 202523$54.2M
Q4 202417$40.9M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 179 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ALDX filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 17, 2026Analysis-
4Nov 16, 2026--
4Nov 13, 2026--
4Nov 13, 2026--
8-KNov 9, 2026Analysis-
10-QNov 5, 2026Analysis
8-KSep 29, 2026Analysis-
SC 13GAug 12, 2026-
10-QAug 6, 2026Analysis
8-KJul 30, 2026Analysis-
8-KJul 15, 2026Analysis-
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
4Jun 11, 2026--
8-KJun 10, 2026Analysis
4Jun 5, 2026-
10-QMay 7, 2026Analysis
8-KMay 1, 2026Analysis-
8-KApr 20, 2026Analysis-
8-KApr 1, 2026--
4Mar 31, 2026--

Related Health Care companies

All Health Care →

ALDX SEC filings: frequently asked questions

Are ALDX insiders buying or selling?

In the last 90 days, Aldeyra Therapeutics, Inc. (ALDX) officers, directors and 10% owners reported 3 open-market purchases worth $140,275 by 3 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ALDX stock?

As of September 30, 2026, the largest Aldeyra Therapeutics, Inc. (ALDX) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($2.9 million), D.E. Shaw & Co ($2.7 million), BlackRock ($1.2 million), Vanguard Portfolio Management LLC ($993,000), AQR Capital Management ($827,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What did ALDX report in its latest 8-K?

Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K on November 17, 2026 reporting Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule). Nasdaq bid-price deficiency after 30 consecutive business days below the $1.00 minimum.

What are the latest ALDX SEC filings?

Aldeyra Therapeutics, Inc. (ALDX) filed its latest 10-K annual report on February 27, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on November 16, 2026.

What is ALDX's SEC CIK number?

Aldeyra Therapeutics, Inc. (ALDX)'s SEC Central Index Key (CIK) is 1341235. EDGAR lists every ALDX filing under that number.

Ask anything about ALDX

The research agent reads ALDX's filings, financials, insider trades and 13F holders, then answers with sources.